Abstract
Evaluation of survival outcomes and response rates among patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) treated with checkpoint inhibitors is of interest. Data regarding overall survival (OS), progression free survival (PFS), response rate, PD-L1 combined positive score (CPS) was retrieved. A total of 412 patients with histo-pathologically confirmed recurrent or metastatic HNSCC who received checkpoint inhibitor (CPI) treatment were ultimately included as members of the cohort. In our study median OS was 13.1 months. Median PFS was 4.1 months. The estimated 1-year OS was 53.9% while estimated 1-year PFS was 9.7%. Our findings support the use of CPI therapies for first- or second-line treatment of recurrent or metastatic HNSCC.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call